Basic Information
| LncRNA/CircRNA Name | LINC00460 |
| Synonyms | NR_034119 |
| Region | GRCh38_13:106374477-106384315 |
| Ensemble | ENSG00000233532 |
| Refseq | NR_034119 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | RNA-seq, Microarray, qRT-PCR, in vitro knockdown |
| Sample | ESCC tissues, Human esophageal cancer cell lines (KYSE150, KYSE180, KYSE450, KYSE70, KYSE140 and TE3) |
| Expression Pattern | up-regulated |
| Function Description | A novel three-lncRNA signature, comprised of RP11-366H4.1.1 (ENSG00000248370), LINC00460 (ENSG00000233532) and AC093850.2 (ENSG00000230838), was identified. The signature classified patients into high-risk and low-risk groups with different overall survival (OS) and disease-free survival (DFS). The signature indicates that patients in the high-risk group show poor OS and DFS, whereas patients with a low-risk group show significantly better outcome. The independence of the signature was validated by multivariable Cox regression analysis. |
| Pubmed ID | 29409459 |
| Year | 2018 |
| Title | A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma. |
External Links
| Links for LINC00460 | GenBank HGNC NONCODE |
| Links for esophageal squamous cell carcinoma | OMIM COSMIC |